tiprankstipranks
Advertisement
Advertisement

SLN Stock Latest News

Blair adds American Express, Oracle to Conviction List in monthly update
The FlyBlair adds American Express, Oracle to Conviction List in monthly update
1d ago
P
CW
Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
PremiumThe Fly
Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
8d ago
SLN
Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald
8d ago
SLN
Silence Therapeutics Updates Strategy and siRNA Pipeline
PremiumCompany Announcements
Silence Therapeutics Updates Strategy and siRNA Pipeline
9d ago
8K
SLN
Silence Therapeutics Shareholders Approve All AGM Resolutions
PremiumCompany Announcements
Silence Therapeutics Shareholders Approve All AGM Resolutions
16d ago
8K
SLN
Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
PremiumRatingsSilence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
21d ago
SLN
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
Premium
Company Announcements
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
21d ago
8K
SLN
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
Premium
The Fly
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
21d ago
SLN
Silence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
PremiumRatings
Silence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
1M ago
SLN
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
PremiumRatings
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
1M ago
SLN
Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
PremiumRatings
Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
1M ago
SLN
Silence Therapeutics Establishes New At-The-Market Program
PremiumCompany Announcements
Silence Therapeutics Establishes New At-The-Market Program
1M ago
8K
SLN
Silence Therapeutics files $300M ordinary shares offering
PremiumThe FlySilence Therapeutics files $300M ordinary shares offering
1M ago
SLN
Silence Therapeutics price target lowered to $27 from $35 at Chardan
Premium
The Fly
Silence Therapeutics price target lowered to $27 from $35 at Chardan
2M ago
SLN
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
Premium
The Fly
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
2M ago
SLN
Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit
PremiumRatings
Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit
4M ago
SLN
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
PremiumCompany Announcements
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
4M ago
8K
SLN
Silence Therapeutics Appoints CFO Rhonda Hellums to Board
PremiumCompany Announcements
Silence Therapeutics Appoints CFO Rhonda Hellums to Board
6M ago
8K
SLN
Silence Therapeutics Announces CEO Departure and Leadership Changes
PremiumCompany Announcements
Silence Therapeutics Announces CEO Departure and Leadership Changes
7M ago
8K
SLN
Silence Therapeutics CEO Craig Tooman to end employment
PremiumThe FlySilence Therapeutics CEO Craig Tooman to end employment
7M ago
SLN
Silence Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Silence Therapeutics Reports Q3 2025 Financial Results
8M ago
SLN
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
Premium
Ratings
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
8M ago
SLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >